spacer
spacer

PDBsum entry 4nnh

Go to PDB code: 
protein Protein-protein interface(s) links
Ribosomal protein PDB id
4nnh

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
164 a.a.
Waters ×129
PDB id:
4nnh
Name: Ribosomal protein
Title: Structural basis for targeting the ribosomal protein s1 of mycobacterium tuberculosis by pyrazinamide
Structure: 30s ribosomal protein s1. Chain: a, b. Fragment: unp residues 285-445. Engineered: yes
Source: Mycobacterium smegmatis. Organism_taxid: 246196. Strain: atcc 700084 / mc(2)155. Gene: rpsa, msmeg_3833, msmei_3743. Expressed in: escherichia coli. Expression_system_taxid: 562.
Resolution:
2.30Å     R-factor:   0.209     R-free:   0.252
Authors: J.Yang,Y.Liu,Q.Cai,D.Lin
Key ref: J.Yang et al. (2015). Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide. Mol Microbiol, 95, 791-803. PubMed id: 25430994 DOI: 10.1111/mmi.12892
Date:
18-Nov-13     Release date:   24-Dec-14    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
A0QYY6  (RS1_MYCS2) -  Small ribosomal subunit protein bS1 from Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155)
Seq:
Struc:
479 a.a.
164 a.a.*
Key:    PfamA domain  Secondary structure
* PDB and UniProt seqs differ at 7 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class: E.C.?
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]

 

 
DOI no: 10.1111/mmi.12892 Mol Microbiol 95:791-803 (2015)
PubMed id: 25430994  
 
 
Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.
J.Yang, Y.Liu, J.Bi, Q.Cai, X.Liao, W.Li, C.Guo, Q.Zhang, T.Lin, Y.Zhao, H.Wang, J.Liu, X.Zhang, D.Lin.
 
  ABSTRACT  
 
Pyrazinamide (PZA) is a first-line drug for tuberculosis (TB) treatment and is responsible for shortening the duration of TB therapy. The mode of action of PZA remains elusive. RpsA, the ribosomal protein S1 of Mycobacterium tuberculosis (Mtb), was recently identified as a target of PZA based on its binding activity to pyrazinoic acid (POA), the active form of PZA. POA binding to RpsA led to the inhibition of trans-translation. However, the nature of the RpsA-POA interaction remains unknown. Key questions include why POA exhibits an exquisite specificity to RpsA of Mtb and how RpsA mutations confer PZA resistance. Here, we report the crystal structures of the C-terminal domain of RpsA of Mtb and its complex with POA, as well as the corresponding domains of two RpsA variants that are associated with PZA resistance. Structural analysis reveals that POA binds to RpsA through hydrogen bonds and hydrophobic interactions, mediated mainly by residues (Lys303, Phe307, Phe310 and Arg357) that are essential for tmRNA binding. Conformational changes induced by mutation or sequence variation at the C-terminus of RpsA abolish the POA binding activity. Our findings provide insights into the mode of action of PZA and molecular basis of PZA resistance associated with RpsA mutations.
 

 

spacer

spacer